00:00 In a significant move, Pfizer has secured regulatory green lights for its acquisition
00:05 of CGen, of course ticker S-G-E-N, valued at $43 million.
00:10 However, Pfizer is anticipating that FY24 revenues to range between $58.5 billion and
00:17 $61.5 billion, factoring CGen's contribution falling short of the consensus estimate of
00:23 $63.17 billion.
00:26 Likewise their projected FY24 adjusted diluted EPS estimated at a range of $2.05 to $2.25
00:33 on the high end, reflecting the anticipated impact of the acquisition, notably lower than
00:39 of course the consensus here of $3.17.
00:43 So Pfizer continuing to get hit here and it's just not a darling.
00:48 No and again this was my fault.
00:50 I put way too much, you know, here I predicted that there would be, you know, less demand
00:55 for the COVID shots in the future and yet I still bought Pfizer on the dip and I was
00:59 way too early on it.
01:00 I mean at a certain point in time it's all going to be priced in and they're going to
01:03 give that zero, which I think that time is now.
01:06 I think it's like priced in now, but I mean this guidance down and again Moderna following
01:12 suit here.
01:13 I know there's some news on Moderna as well.
01:15 BNTX following suit here today.
01:17 I mean these Pfizer earnings falling are a lot to do with it.
01:20 They were really fluffed up from the COVID shots and people aren't getting them anymore,
01:23 very few people.
01:25 So that's where a lot of these, you know, is coming from here.
01:28 Stock is eventually going to get to a point where it's just too cheap to ignore.
01:33 It's not like this is a startup pharma company.
01:35 This is one of the biggest pharmaceutical companies in the world.
01:37 It's going to do a lot of things, but they don't like it right now.
01:39 They love Lilly.
01:40 They hate Pfizer.
01:42 Maybe that trade sets up to reverse in January too and start writing these down.
01:46 Oil, Pfizer, your dogs typically going to my January effect, not the textbook January
01:52 effect is that the leaders become laggards and the laggards become leaders the first
01:56 couple of weeks of January.
01:57 There is no laggard bigger than Pfizer, Alibaba, you know, the oil stocks to a certain extent
02:04 all laggards.
02:05 Those are the stocks I'm looking at January 1st, but this is December 13th.
02:09 You don't want to be early.
02:11 I will say though, Pfizer is starting to get attracted from an evaluation perspective.
02:16 Big plunge and I mean, they did, they did not hold back at all.
02:20 Maybe volume took it down to 2610 and you've got a bounce over 27.
02:25 So I'd use those parameters.
02:27 26 is probably a big whole number as well.
02:31 But I think what the most important point to bring up here is, you know, when Pfizer
02:36 was having that run member and I don't know if I could pronounce the CEO's name, right?
02:42 Albert Borla or whatever.
02:43 Do you remember what he was doing with his stock?
02:48 You're sour.
Comments